The Future of Cannabis Legalisation: Rescheduling and What It Changes

Federal cannabis reform gets discussed as a single event. It is several distinct mechanisms that would produce very different outcomes, and knowing which is which makes the news considerably easier to read.

Where Things Stand

Cannabis is a Schedule I controlled substance under the US Controlled Substances Act, the category defined as high abuse potential with no currently accepted medical use. That classification has always been in tension with state medical programmes and, more awkwardly, with the FDA having approved Epidiolex, a cannabis-derived medicine.

A process to move cannabis to Schedule III has been under way, following a health agency recommendation and a Department of Justice proposal. Schedule III covers substances with accepted medical use and moderate to low dependence potential.

What Rescheduling to Schedule III Would Change

Section 280E stops applying. This is the largest practical effect. Section 280E denies ordinary business deductions to businesses trafficking in Schedule I or II substances. Schedule III is neither, so licensed operators could deduct rent, payroll and marketing like any other business. That single change would transform cannabis business economics more than anything else on the table.

Research becomes easier. Schedule I research requires registrations and approvals that have severely limited cannabis study for decades. Lowering the schedule reduces that barrier, which matters for a field where the most common conclusion is that evidence is insufficient.

Federal acknowledgement of medical use, which has symbolic and regulatory consequences.

What Rescheduling Would Not Change

This is where most confusion lives.

State-legal markets would still not be federally legal. Schedule III substances require a prescription and FDA approval to be dispensed lawfully. A dispensary selling flower for adult use remains outside federal law.

Banking would not automatically be fixed, since the underlying conduct remains federally unlawful.

Interstate commerce would still be prohibited.

Employment protections would not be created. Federally regulated testing would continue.

Existing convictions would not be cleared.

Immigration consequences would largely persist.

So rescheduling is a substantial change to industry economics and research access, and it is not legalisation.

Descheduling Is the Bigger Step

Descheduling would remove cannabis from the Controlled Substances Act entirely, as happened with hemp under the 2018 Farm Bill. That is closer to what most people mean by federal legalisation, and it raises questions rescheduling avoids: which agency regulates products, what happens to interstate commerce, how state markets integrate, and what federal taxation looks like.

Various bills have proposed descheduling with regulatory frameworks and social equity provisions. None has become law.

Banking Legislation

The SAFE Banking Act, and later versions, would provide protections for financial institutions serving state-legal cannabis businesses. It has passed the House of Representatives on multiple occasions without becoming law.

Its effects would be narrower than rescheduling and immediate: lower capital costs, less cash handling, reduced robbery risk and better payment processing. For operators it is one of the more consequential possible changes.

International Constraints

Domestic reform interacts with treaty obligations. The 1961 Single Convention on Narcotic Drugs commits signatories to controlling cannabis, which is one reason countries have used medical frameworks and decriminalisation rather than outright legalisation.

Movement has occurred. Following a World Health Organization recommendation, the UN Commission on Narcotic Drugs removed cannabis from Schedule IV of the 1961 Convention, its most restrictive category, in 2020. Canada and Uruguay legalised while remaining parties to the treaties, which has been noted as a tension without producing consequences.

What To Watch

Whether rescheduling is completed, and how the resulting rules treat existing state markets.

Banking legislation, which could pass independently.

State tax restructuring, as jurisdictions respond to illicit market persistence.

Interstate commerce litigation and compacts, where states have explored agreements that would take effect if federal law permits.

Hemp-derived intoxicants, since the delta-8 market created by the Farm Bill's delta-9 wording is prompting regulatory responses that may reshape the wider framework.

Price and consolidation trends, which will determine what industry survives to operate under any new rules.

Bottom Line

Rescheduling to Schedule III would end Section 280E's application and ease research restrictions, which matters enormously to operators and researchers, and it would not make state markets federally legal, fix banking, permit interstate commerce or clear convictions. Descheduling is the step that would do those things, banking legislation is a narrower and more immediate fix, and treaty obligations shape how far countries go.

Disclaimer: This article is for educational purposes only and does not constitute legal advice. Cannabis law changes frequently. Verify current rules for your jurisdiction.